Sunshine Biopharma, Inc. - SBFM Operating profit EBITDA
Sunshine Biopharma (SBFM) combines the production of generics with the search for new oncology treatments to achieve self-financing. The EBITDA on the GURU.Markets chart clearly demonstrates the trend, where 0.00 records a new level. However, fierce competition in the pharmaceutical sector and a constant shortage of funds due to loss-making developments leave the company dependent on third-party investments.
Sunshine Biopharma - analytical breakdowns and key metrics (SBFM)
- current quotes and average value forecast:
- issuer market value details:
- book value of equity indicators:
- debt level and financial liquidity data:
Total Debt to Capital Coefficient Sunshine Biopharma|SBFM - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital sunshinebiopharma.com|SBFM - Company Debts|Debt to Book Value Ratio Sunshine Biopharma|SBFM - Company Long-Term Debt|Short-Term Debt Volume Sunshine Biopharma|Intermediate Coverage Ratio sunshinebiopharma.com
- earnings and market ratios statistics:
SBFM - Net Profit|Company Profit Forecast Sunshine Biopharma|SBFM - Price to Earnings Ratio|Price to Future Earnings Ratio Sunshine Biopharma Inc.|SBFM - PEG Multiple|Company Value to EBITDA Sunshine Biopharma|SBFM - Operating profit before deduction of amortization|Earnings per share for the trailing year Sunshine Biopharma|SBFM - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months sunshinebiopharma.com|SBFM - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Sunshine Biopharma
Analysis of all company metrics:Sunshine Biopharma Inc. - SBFM
This metric reflects the actual cash flow from core operations before depreciation and taxes, allowing investors to strip away one-time factors and assess the sustainability of operational efficiency. Analyzing absolute operating profit is critical for Sunshine Biopharma (SBFM), as future pricing power derived from intellectual property on anti-cancer drugs transforms current expenditures into large-scale monopoly profits.
Competitors of Sunshine Biopharma (SBFM)
ONC - Operating profit before deduction of amortization|HALO: Operating profit before deduction of amortization|RVMD - Operating profit EBITDA|Ascentage Pharma (AAPG) - Profit before payment of interest, taxes and amortization|CG Oncology Inc - Income before deduction of interest, taxes and amortization|URGN (UroGen) - Operating profit EBITDA|Profit before interest, taxes and amortization Bicara Corp BCAX|Profit before payment of interest, taxes and amortization Personalis, Inc. (PSNL)|Operating income before deduction of amortization erasca.com|Delcath Systems - Operating profit before deduction of amortization|Operating profit EBITDA Y-mAbs Therapeutics Inc YMAB|AURA - Profit before payment of interest, taxes and amortization|CADL (Candel Therapeutics) - Operating profit before amortization|Accuray Incorporated (ARAY) - Profit before payment of interest, taxes and amortization|SLS - Operating income before deduction of amortization|ACTU (Actuate Therapeutics) - Operating profit EBITDA|CTOR: Income before deduction of interest, taxes and amortization|Operating profit EBITDA HURA|Operating income before deduction of amortization Protara Tx|Profit before payment of interest, taxes and amortization Fate Therapeutics, Inc. FATE|WHWK: Operating profit before amortization|TScan - Operating profit EBITDA|Profit before interest, taxes and amortization Champions Oncology|XBIT (xbiotech.com) - Operating profit before deduction of amortization|CEL-SCI - Income before deduction of interest, taxes and amortization|OSTX (OS Therapies Incorporated) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization RADX|Operating profit EBITDA ARTV|Operating income before deduction of amortization adlainortye.com|Profit before payment of interest, taxes and amortization Veru Pharma VERU|Tempest Therapeutics Corp (TPST) - Profit before interest, taxes and amortization|XLO - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization RENB|MURA: Operating profit EBITDA|Kairos Pharma - Income before deduction of interest, taxes and amortization|OKUR (OnKure Therapeutics, Inc.) - Operating profit EBITDA|Operating profit EBITDA CytoMed|Profit before payment of interest, taxes and amortization Curis, Inc. (CRIS)|APLM (apollomicsinc.com) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Tharimmune THAR|ADVB - Operating profit before deduction of amortization|Genprex, Inc - Operating profit EBITDA|CLDI - Operating profit EBITDA|xeneticbio.com (XBIO) - Profit before payment of interest, taxes and amortization|SLRX - Operating income before deduction of amortization|PPBT (Purple Biotech Ltd.) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization AONC|Operating profit EBITDA BGNE|CKPT: Profit before deduction of interest, taxes, depreciation and amortization|Profit before payment of interest, taxes and amortization Elevation Oncology ELEV|ICAD - Operating profit before deduction of amortization|Ikena - Operating profit EBITDA|Notable Labs Ltd (NTBL) - Operating profit before deduction of amortization|VIRX: Operating profit EBITDA|MorphoSys Corporation (MOR) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization NAYA Biosciences|Operating profit before amortization AAPGV (ascentage.com)
